SCHEDULE: Redmile Group Discloses 8% Stake in Stoke Therapeutics
Ownership Disclosure
Redmile Group, LLC and its principal Jeremy C. Green have reported an 8.0% beneficial ownership stake in Stoke Therapeutics, Inc.
Summary
- Redmile Group, LLC, an investment adviser, and its principal, Jeremy C. Green, collectively hold 4,375,931 shares of Stoke Therapeutics, Inc. common stock.
- This ownership represents an 8.0% stake in Stoke Therapeutics, Inc.'s common stock.
- Redmile Biopharma Investments III, L.P., one of the private investment vehicles managed by Redmile Group, LLC, directly owns 3,505,612 shares, representing 6.4% of the class.
- The percentage ownership is based on 54,596,924 shares of common stock outstanding as of April 30, 2025, as reported by Stoke Therapeutics, Inc. in its Form 10-Q filed on May 13, 2025.
- Redmile Group, LLC and Jeremy C. Green disclaim beneficial ownership of these shares, except to the extent of their pecuniary interest.
Sentiment
Score: 7
Explanation: The filing indicates a significant and continued investment by a specialized biopharma investment firm, suggesting confidence in the issuer's long-term prospects. This is generally viewed positively by the market.
Positives
- The disclosure of an 8.0% beneficial ownership by Redmile Group, LLC, a specialized biopharma investment firm, signals significant institutional confidence in Stoke Therapeutics, Inc.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders may view the significant stake held by Redmile Group, LLC as a positive signal of institutional confidence in Stoke Therapeutics, Inc.'s future performance and strategic direction.
Key Dates
| Date | Description |
|---|---|
| 2025-04-30 | Date as of which 54,596,924 shares of Common Stock were outstanding, as reported by the Issuer in its Form 10-Q. |
| 2025-05-13 | Date Stoke Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended March 31, 2025. |
| 2025-06-30 | Date of event which requires filing of this statement (reporting period end). |
| 2025-08-14 | Date the Schedule 13G Amendment No. 5 was signed and filed. |
Keywords
Stoke Therapeutics, Redmile Group, Biopharma, Investment, Ownership, Institutional Investor, Common Stock, SEC Filing, STOK
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.